Pfizer expands recall of Chantix over presence of cancer causing agents

Published On 2021-08-15 05:00 GMT   |   Update On 2021-08-15 05:00 GMT

New Delhi: Pfizer Inc said on Friday it is recalling four additional lots of its anti-smoking treatment, Chantix, after finding elevated levels of cancer-causing agents called nitrosamines in the pills.

In June, the drugmaker said it was pausing distribution of certain lots of the anti-smoking drug out of an abundance of caution and pending further testing.

Read also: Pfizer halts distribution of anti-smoking treatment Chantix over presence of cancer causing agents

Including Friday's recall, Pfizer has paused distribution of 16 lots of the drug. The lots were distributed to wholesalers in the United States and Puerto Rico from June 2019 to June 2021.

Pfizer said that so far it has not received any reports of adverse events related to this recall, but advised patients currently taking Chantix to consult with their doctor to confirm if they received an affected lot and seek alternative treatment options if appropriate.

Chantix was approved by the U.S. Food and Drug Administration in May 2006 as a prescription medication which helps adults aged 18 and over quit smoking and is used for 12 to 24 weeks.

Read also: India in discussion to buy 50 million Pfizer COVID vaccine doses: Report



Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News